NICOTROL INHALER Rx
Generic Name and Formulations:
Nicotine inhalation system 10mg (4mg delivered); per cartridge; contains menthol.
McNeil Consumer Healthcare
Indications for NICOTROL INHALER:
Adjunct in smoking cessation therapy.
Each cartridge lasts about 20 minutes with frequent continuous puffing and provides nicotine equivalent to about 2 cigarettes. Individualize. Use at least 6 cartridges/day for 1st 3–6 weeks; max 16 cartridges/day for 1st 12 weeks, then reduce gradually over 12 more weeks.
Concurrent smoking or other nicotine products.
Avoid immediately post-MI, in arrhythmias, or severe or worsening angina pectoris. Hypertension. Vasospastic or coronary heart disease. Hepatic or severe renal impairment. Hyperthyroidism. Pheochromocytoma. Diabetes. Peptic ulcer disease. Elderly. Low doses may be toxic to children and pets. Nasal Spray not recommended in chronic nasal disorders. Pregnancy (Cat.D), labor & delivery: not recommended (attempt nondrug treatment first). Nursing mothers.
Nasal Spray antagonized by nasal vasoconstrictors. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Inhaler 42 cartridges—1 (w. inhaler and case); Nasal Spray 10mL (200 sprays)—1 (w. metered spray pump)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally